Predictors of premature discontinuation of treatment in multiple disease states

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 31-43

  Nantz, Eric ^a   Liu Seifert, Hong ^b   Skljarevski, Vladimir ^b  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse event; Attrition; Depression; Fibromyalgia; Generalized anxiety disorder; Therapeutic response

Indexed keywords

EID: 77958466567     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4633     Document Type: Article

References (24)

1. Connor KM. Treatment of generalized anxiety disorder: current options and future developments. In: Culpepper L, chair. Effective recognition and treatment of generalized anxiety disorder in primary care [ACADEMIC HIGHLIGHTS]. Prim Care Companion J Clin Psychiatry. 2004;6:35-41.
2. Shelton R. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry. 2001;3:168-174.
3. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry. 2007;59:1001-1005.
4. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with diabetic neuropathy. Pain. 2005;116(1-2):109-118.
5. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253-260.
6. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81-104.
7. Vinik A, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128(1-2):169-179.
8. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9(5):543-554.
9. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120(5):448-454.
10. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multi-center trial. Arthritis Rheum. 2007;56(4):1336-1344.
11. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):S27-S35.
12. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-1273.
13. Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med. 2007;8(8):633-638.
14. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182-189.
15. Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo-controlled, flexible-dose study. Depress Anxiety. 2004;19(4):234-240.
16. Rickels D, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(4):749-756.
17. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533-540.
18. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment of depression: a STAR*D report. Am J Psychiatry. 2007;164:1189-1197.
19. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;23:21.
20. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005;25:660-667.
21. Collett D. Modelling Survival Data in Medical Research. 2nd. ed. London: Chapman and Hall/CRC, 2003.
22. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation Symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73-84.
23. Moser DK, Dracup K, Doering LV. Factors differentiating dropouts from completers in a longitudinal, multicenter clinical trial. Nurs Res. 2000;49(2):109-116.
24. Khan A, Schwartz K, Redding N, Kolts RL, Brown WA. Psychiatric diagnosis and clinical trial completion rates: Analysis of the FDA SBA reports. Neuropsychopharmacology. 2007;32:2422-2430.